

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

VOLUNTARY ANNOUNCEMENT

“DOXAZOSIN MESYLATE EXTENDED-RELEASE TABLETS” APPROVED FOR MARKETING

The board of directors (the “**Board**”) of Fusen Pharmaceutical Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that “Doxazosin Mesylate Extended-Release Tablets” (trademark: Yijianping) developed by Henan Fusen Pharmaceutical Company Limited (河南福森藥業有限公司), a wholly-owned subsidiary of the Company, has obtained the approval for marketing from the National Medical Products Administration of the PRC (國家藥品監督管理局) for hypertension and the symptomatic treatment of benign prostatic hyperplasia.

“Doxazosin Mesylate Extended-Release Tablets” has become a first-line drug both domestically and internationally for the treatment of mild to moderate hypertension, as well as a first-line treatment for benign prostatic hyperplasia with associated lower urinary tract symptoms. The tablets offer several advantages: rapid onset, long-lasting effects, more stable release, significant efficacy, ease of use, and are unaffected by age or mild to moderate renal impairment.

“Doxazosin Mesylate Extended-Release Tablets” are selective alpha-1 receptor inhibitors. Doxazosin mesylate counteracts prostate contraction in the human body induced by phenylephrine (an alpha-1 receptor agonist), which reduces peripheral vascular resistance to lower blood pressure. Additionally, it lowers urethral resistance, which helps alleviate symptoms of benign prostatic hyperplasia and improves urine flow.

“Doxazosin Mesylate Extended-Release Tablets” is a Class B drug under the National Reimbursement Drug List, and has been recommended by several domestic guidelines in the PRC, including the *Guideline for Integrated Chinese and Western Medicine Multidisciplinary Diagnosis and Treatment of Benign Prostatic Hyperplasia*, the *Expert Consensus on Treatment and Prevention Measures for Bladder Function Damage Secondary to Elderly Benign Prostatic Hyperplasia*, and the *Expert Consensus on Integrated Chinese and Western Medicine Drug Treatment for Chronic Prostatitis*. According to data from Menet, the sales scale of such drug across three major terminals and six major markets in the PRC has expanded year by year. In 2025, the sales amount exceeded RMB800 million for the first time, representing a year-on-year increase of 27.88%, and ranked first in the anti-hypertensive drug product category.

“Doxazosin Mesylate Extended-Release Tablets” is another important pharmaceutical product of the Group and the Company’s first new sustained-release and controlled-release pharmaceutical product using laser drilling technology, further enriching our product pipeline. Once launched, this product will provide additional treatment options for patients with benign prostatic hyperplasia and hypertension.

By order of the Board
Fusen Pharmaceutical Company Limited
Mr. Cao Zhiming
Chairman and Executive Director

Hong Kong, 10 July 2026

As at the date of this announcement, the Board of the Company comprises Mr. Cao Zhiming (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng and Ms. Meng Qingfen as executive directors, and Mr. Lee Kwok Tung Louis, Dr. To Kit Wa and Mr. Yu Ho Ming as independent non-executive directors.